US › Healthcare

Theriva Biologics Inc. (TOVX)

US · Healthcare · Biotechnology

$0.24+7.08%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-3.2M

EPS

$-0.07

EPS estimate

$-0.05

EPS came in at -0.07 against a street estimate of -0.05 — a miss of 40.0%.

Key statistics

Market cap

$10.3M

P/E

0.2

Forward P/E

0.0

P/B

0.89

Book value

$0.27

EPS (TTM)

$1.44

52-week high

$0.86

52-week low

$0.16

50-day MA

$0.23

200-day MA

$0.24

Beta

1.15

Analyst view

Analysts rate Theriva Biologics Inc. a buy (1 buy, 1 hold, 0 sell out of 2) with an average price target of $2.50.

Shareholding

Insiders

1.63%

Institutions

4.35%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Theriva Biologics Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.